Recombinant luteinizing hormone supplementation based on FSH/LH values will improve clinical outcomes with antagonist protocol: a prospective, single-center, single-blind, randomized controlled trial

INTERVENTION: Experimental group:Administer gene recombinant follicle‐stimulating hormone (r‐FSH) 150‐225u + gene recombinant luteinizing hormone (r‐LH) 75u, inject once a day, for 5 consecutive days, the sixth day of stimulation (the sixth day of stimulation) according to adjust the dosage of r‐LH according to the FSH/LH value (if >= 5r‐LH, increase to 150 u/d, if < 5r‐L1, the dosage remains unchanged) until the night needle day.;Control group:From the start date, r‐FSH (150‐225u) was injected once a day for 5 consecutive days, and 75u r‐LH was added on the 6th day according to the current clinical routine until the night acupuncture day.; CONDITION: Infertility PRIMARY OUTCOME: good‐quality cleavage embryos; SECONDARY OUTCOME: follicle export rate;MII oocyte rate;fertility rate;available embryo rate;good embryo rate;Clinical pregnancy rate;Pregnancy loss rate; INCLUSION CRITERIA: 1. The age of the woman is 20‐40 years old, and the menstrual cycle is normal; 2. Both husband and wife have normal chromosomes; 3. Without adenomyosis and endometriosis; 4. No intramural fibroids > 4 cm, intrauterine adhesions or untreated endometrial polyps.